The ongoing MARGOT phase 2 randomized open‐label trial (NCT04425018) will compare neoadjuvant margetuximab to trastuzumab (both with pertuzumab plus paclitaxel) in patients with stage II–III HER2‐positive breast cancer who are low‐affinity CD16A‐158F carriers. Here, ERBB2 is linked to breast cancer.